Results 21 to 30 of about 17,658 (183)
Ranibizumab in neovascular age-related macular degeneration
Clinical Interventions in Aging, 2006 Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF).
T Eng, Kenneth, Peter J, Kertes
openaire +2 more sources
EBioMedicine, 2018 Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in developed countries. Neovascular AMD (nAMD) accounts for 90% of AMD-related vision loss.
Karis Little +4 more
doaj +1 more source
Aflibercept for neovascular age-related macular degeneration
Cochrane Database of Systematic Reviews, 2016 Central vision loss caused by age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in developed countries. Neovascular AMD is characterized by choroidal neovascularization (CNV). Growth of new blood vessels in patients with neovascular AMD is driven by a complex process that involves a signal protein called ...
Salman, Sarwar +9 more
openaire +3 more sources
Brolucizumab-induced retinal vasculitis – An Indian perspective
Indian Journal of Ophthalmology. Case Reports, 2022 The case of retinal vasculitis in a one-eyed elderly diabetic female after use of brolucizumab injection (second dose) for neovascular age-related macular degeneration.
Manpreet Brar +4 more
doaj +1 more source
New Therapies of Neovascular AMD beyond Anti-VEGF Injections
Vision, 2018 Neovascular age-related macular degeneration is a leading cause of vision loss among the aging population. The current standard of care to treat neovascular age-related macular degeneration is inhibiting vascular endothelial growth factor (VEGF) through ...
Greggory M. Gahn, Arshad M. Khanani
doaj +1 more source
Unusual visual loss in a patient with exudative macular degeneration
American Journal of Ophthalmology Case Reports, 2022 Purpose: To describe a case of marked vision loss in a patient with neovascular age-related macular degeneration after choroidal neovascular membrane (CNV) improvement and stabilization.
Enoch T. Peng, Sean D. Adrean
doaj +1 more source
Advanced Science, EarlyView.Eligibility flow and real‐world AMD burden in the UKB retinal imaging cohort and TMUEH external‐validation cohort. Overview of the ORBIT‐AMD architecture, integrating retinal representation pretraining, bilateral eye‐graph modeling and concept bottleneck learning to support ordered risk, bilateral context, interpretable lesion concepts, longitudinal ...
Xuehao Cui +3 more
wiley +1 more source
Evaluation of Flowmetry Indicators in Patients with a Wet AMD Form during Antiangiogenic Therapy
Oftalʹmologiâ, 2019 Purpose: to assess the effect of aflibercept (Eylea; “Regeneron”, USA) intravitreal injections on ocular blood flow and intraocular pressure parameters in patients with neovascular form of age-related macular degeneration (wet AMD).
N. Yu. Yousef +5 more
doaj +1 more source
Quantitative Autofluorescence in Non-Neovascular Age Related Macular Degeneration
Biomedicines, 2023 Quantitative autofluorescence (qAF8) level is a presumed surrogate marker of lipofuscin content in the retina. We investigated the changes in the qAF8 levels in non-neovascular AMD. In this prospective cohort study, Caucasians aged ≥50 years with varying
Shruti Chandra +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.When setting the price of cell and gene therapies in Japan, the factors considered include the manufacturing and operating costs of the new drug or a comparator, leading to discrepancies between price and values, in particular those specific to cell and gene therapies.
Akina Takami, Ataru Igarashi
wiley +1 more source